NCT02924038View on ClinicalTrials.gov

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

PHASE1TerminatedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

GliomaMalignant GliomaAstrocytoma, Grade IIOligodendrogliomaGlioma, AstrocyticOligoastrocytoma, Mixed

Interventions

BIOLOGICAL

IMA950

IMA950 vaccine

BIOLOGICAL

poly-ICLC

poly-ICLC vaccine

BIOLOGICAL

Varlilumab

Intravenous solution

Trial Locations (1)

94143

University of California, San Francisco

Sponsors

Collaborators (1)

Celldex Therapeutics

All Listed Sponsors

collaborator

Celldex Therapeutics

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Nicholas Butowski

OTHER

NCT02924038 - A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | Biotech Hunter | Biotech Hunter